Search

Øie MR, Helvik AS, Sue-Chu M, Steinsvåg SK, Thorstensen WM. Int J Chron Obstruct Pulmon Dis. 2022;17:2137–2147. Page 2137, Abstract, Patients and Methods section, line 2, the text “in 93 COPD patients” should read “in 90 COPD patients”. The authors have also advised Figure 1 on page 2138 is incorrect. Without RSsNP should be n=44 and With RSsNP should be n=46. The correct Figure 1 is as follows. Figure 1 Flow chart of the study participants and the subjects excluded. Abbreviations: EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps (2012); RSsNP, Rhinosinusitis sin Nasal Polyps.

Marte Rystad Øie,1,2 Anne-Sofie Helvik,1,3 Malcolm Sue-Chu,4,5 Sverre Karmhus Steinsvåg,6,7 Wenche Moe Thorstensen1,2 1Department of Otolaryngology, Head and Neck Surgery, St. Olavs hospital, 7006 Trondheim University Hospital, Trondheim, Norway; 2Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 3Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 5Department of Thoracic Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway; 6Department of Otolaryngology, Head and Neck Surgery, Sørlandet Hospital, Kristiansand, 4604, Norway; 7Haukeland University Hospital, Bergen, NorwayCorrespondence: Marte Rystad Øie, Department of Otolaryngology, Head and Neck Surgery, St. Olavs hospital, Trondheim University Hospital, 3250 Torgarden, Trondheim, NO-7006, Norway, Tel +47 926 42 329, Email marte.oie@gmail.com; marte.r.oie@ntnu.noPurpose: Sinonasal symptoms are prevalent in COPD, and knowledge of the relationship between these symptoms and clinical markers of COPD is limited. This study explores the associations between the burden of sinonasal symptoms and clinical markers and thresholds recommended for guiding treatment decisions in the GOLD guidelines.Patients and Methods: Sinonasal symptoms were quantified with the rhinological subscale of the Sino-Nasal-Outcome-Test (SNOT-22) in 93 COPD patients characterized by the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2012 diagnostic criteria for rhinosinusitis without nasal polyps (RSsNP). Associations between a high burden, defined as a SNOT22_rhinological score of ≥ 11, and the following markers were assessed by adjusted multivariable linear regressions; severity of dyspnea [modified Medical Research Council (mMRC)] and cough [Visual Analogue Scale (VAS)], physical activity [6-minute walking distance (6MWD)], mortality risk (BODE index), and HRQoL [disease-specific COPD Assessment Test (CAT) and St. Georges Respiratory Questionnaire (SGRQ), and physical component summary, Short Form-36 version 2.0 (PCS SF-36v2)]. Odds ratios for the association of a high burden and threshold levels for regular treatment were estimated by adjusted binomial logistic regression models.Results: A high burden was associated with greater severity of dyspnea and cough, lower 6MWD, higher BODE index and poorer HRQoL. The odds ratio of having CAT and SGRQ scores that are above the thresholds recommended for treatment was 5– 7-fold greater in the high burden group.Conclusion: A high burden of sinonasal symptoms is positively associated with the clinical markers of symptom severity and mortality risk and is inversely associated with physical activity and HRQoL in COPD. These findings add further support that the UAD concept also applies to COPD. Enquiry about sinonasal symptoms in COPD patients should be incorporated into the clinical routine.Keywords: united airways disease, chronic nasal symptoms, rhinosinusitis, HRQoL